In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
Abstract
Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to obtain a sufficient number of functional DCs. Theoretically, this limitation can be overcome by using induced pluripotent stem cells (iPSCs); however, therapeutic strategies to engage iPSC-derived DCs (iPSC-DCs) into cancer immunotherapy remain to be elucidated. Accumulating evidence showing that induction of tumor-residing DCs enhances immunomodulatory effect of radiotherapy (RT) prompted us to investigate antitumor efficacy of combining intratumoral administration of iPSC-DCs with local RT.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2021
- Source ID
- 10.1136/jitc-2021-002432
Entities
People
- Alfred E Chang
- Fumito Ito
- Hans Minderman
- Kenichi Makino
- Kunle Odunsi
- Masumi Abe
- Ryoko Araki
- Ryutaro Kajihara
- Takaaki Oba
- Toshihiro Yokoi
Organizations
- Melanoma Research Alliance
- National Cancer Institute
- Sarcoma Foundation of America
- Uehara Memorial Foundation
- United States Department of Defense